30020 Federal Register / Vol. 72, No. 103 / Wednesday, May 30, 2007 / Notices 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel; MBRS Support of Competitive 

Research. 

Date: June 19, 2007. 

Time: 8:30 a.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Margaret J. Weidman, PhD, 

Office of Scientific Review, National Institute 

of General Medical Sciences, National 

Institutes of Health, 45 Center Drive, Room 

3AN18B, Bethesda, MD 20892, 301–594–

3663, weidmanma@nigms.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives, National 

Institutes of Health, HHS) 

Dated: May 22, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2665 Filed 5–29–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institutes of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Clinical Trial 

Planning Grants. 

Date: June 18, 2007. 

Time: 10 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

Room 3200, Bethesda, MD 20817 (Telephone 

Conference Call). 

Contact Person: Stefani T. Rudnick, PhD, 

Scientific Review Administrator, Scientific 

Review Program, Division of Extramural 

Activities, NIH/NIAID/DHHS, 6700B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892–7616, 301–496–2550, 

srudnick@niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Th2 Cell Development, 

Persistence and Exhaustion. 

Date: June 21, 2007. 

Time: 11 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

Room 3144, Bethesda, MD 20817 (Telephone 

Conference Call). 

Contact Person: Thames E. Pickett, PhD, 

Scientific Review Administrator, Scientific 

Review Program, Division of Extramural 

Activities, National Institutes of Health/ 

NIAID/DHHS, 6700B Rockledge Drive, MSC 

7616, Bethesda, MD 20892–7616, 301–496–

2550, pickettte@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: May 23, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2671 Filed 5–29–07; 8:45 am] 

BILLING CODE 4140–07–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Roadmap—Facilitating Interdisciplinary 

Research. 

Date: July 9–10, 2007. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate, 2650 Virginia 

Avenue, NW., Washington, DC 20037. 

Contact Person: Gerald L. McLaughlin, 

PhD, Scientific Review Administrator, Office 

of Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 220, MSC 

8401, 6101 Executive Blvd, Bethesda, MD 

20892–8401, 301–402–6626, 

gm145a@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: May 23, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2672 Filed 5–29–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

inform the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Muscular Dystrophy 

Coordinating Committee. 

Date: June 25, 2007. 

Time: 8 a.m. to 3 p.m. 

Agenda: Policy Discussion. 

Place: Crowne Plaza Hotel, 8777 Georgia 

Avenue, Silver Spring, Maryland 20910, 

Phone: 301–587–4791. 

Contact Person: John D. Porter, PhD, 

Executive Secretary, Muscular Dystrophy 

Coordinating Committee, National Institute 

of Neurological Disorders and Stroke, NIH, 

6001 Executive Boulevard, NSC 2172, 

Bethesda, MD 20892, (301) 496–1917, 

porterjo@ninds.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 


sroberts on PROD1PC70 with NOTICES